![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: RASGEF1B |
Gene summary for RASGEF1B |
![]() |
Gene information | Species | Human | Gene symbol | RASGEF1B | Gene ID | 153020 |
Gene name | RasGEF domain family member 1B | |
Gene Alias | GPIG4 | |
Cytomap | 4q21.21 | |
Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | Q0VAM2 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
153020 | RASGEF1B | HCC2_Meng | Human | Liver | HCC | 7.90e-08 | -1.53e-01 | 0.0107 |
153020 | RASGEF1B | HCC1 | Human | Liver | HCC | 5.26e-64 | 2.13e+00 | 0.5336 |
153020 | RASGEF1B | P1_S1_AK | Human | Skin | AK | 8.15e-24 | 7.24e-01 | -0.3399 |
153020 | RASGEF1B | P2_S3_AK | Human | Skin | AK | 4.28e-08 | 4.34e-01 | -0.3287 |
153020 | RASGEF1B | P3_S6_AK | Human | Skin | AK | 4.40e-15 | 6.06e-01 | -0.3256 |
153020 | RASGEF1B | P4_S8_cSCC | Human | Skin | cSCC | 4.06e-02 | 2.51e-01 | -0.3095 |
153020 | RASGEF1B | P5_S10_cSCC | Human | Skin | cSCC | 3.09e-10 | 2.61e-01 | -0.299 |
153020 | RASGEF1B | male-WTA | Human | Thyroid | PTC | 3.04e-03 | 6.55e-02 | 0.1037 |
153020 | RASGEF1B | PTC05 | Human | Thyroid | PTC | 3.66e-15 | 7.26e-01 | 0.2065 |
153020 | RASGEF1B | PTC06 | Human | Thyroid | PTC | 1.25e-17 | 5.78e-01 | 0.2057 |
153020 | RASGEF1B | PTC07 | Human | Thyroid | PTC | 1.62e-05 | 1.70e-01 | 0.2044 |
153020 | RASGEF1B | ATC13 | Human | Thyroid | ATC | 3.64e-09 | 1.77e-01 | 0.34 |
153020 | RASGEF1B | ATC5 | Human | Thyroid | ATC | 2.26e-06 | 1.99e-01 | 0.34 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RASGEF1B | SNV | Missense_Mutation | c.705N>C | p.Gln235His | p.Q235H | Q0VAM2 | protein_coding | tolerated(0.57) | benign(0.006) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
RASGEF1B | SNV | Missense_Mutation | c.1239G>A | p.Met413Ile | p.M413I | Q0VAM2 | protein_coding | tolerated(0.96) | benign(0.001) | TCGA-AQ-A04J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
RASGEF1B | insertion | Nonsense_Mutation | novel | c.745_746insAGCCACTGTAATAT | p.Arg249GlnfsTer4 | p.R249Qfs*4 | Q0VAM2 | protein_coding | TCGA-E9-A1NC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR | ||
RASGEF1B | SNV | Missense_Mutation | c.247G>A | p.Val83Ile | p.V83I | Q0VAM2 | protein_coding | tolerated(0.14) | benign(0.206) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
RASGEF1B | SNV | Missense_Mutation | rs373675008 | c.1171C>T | p.Arg391Cys | p.R391C | Q0VAM2 | protein_coding | deleterious(0.02) | probably_damaging(0.953) | TCGA-AA-3848-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
RASGEF1B | SNV | Missense_Mutation | c.346N>A | p.Glu116Lys | p.E116K | Q0VAM2 | protein_coding | deleterious(0.04) | possibly_damaging(0.897) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
RASGEF1B | SNV | Missense_Mutation | c.179N>T | p.Arg60Ile | p.R60I | Q0VAM2 | protein_coding | deleterious(0.01) | possibly_damaging(0.781) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
RASGEF1B | SNV | Missense_Mutation | c.547N>A | p.Asp183Asn | p.D183N | Q0VAM2 | protein_coding | tolerated(0.06) | benign(0.196) | TCGA-WS-AB45-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
RASGEF1B | SNV | Missense_Mutation | novel | c.750N>T | p.Lys250Asn | p.K250N | Q0VAM2 | protein_coding | deleterious(0.02) | benign(0.16) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
RASGEF1B | SNV | Missense_Mutation | c.1046G>A | p.Arg349Gln | p.R349Q | Q0VAM2 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |